Vivos Therapeutics Raises $4.6 Million Through Warrant Exercise at Reduced Price

Reuters01-21
<a href="https://laohu8.com/S/VVOS">Vivos Therapeutics</a> Raises $4.6 Million Through Warrant Exercise at Reduced Price

Vivos Therapeutics Inc. announced that it has entered into a warrant inducement agreement with an institutional investor, resulting in the exercise for cash of previously issued warrants to purchase shares of its common stock. The warrants, originally exercisable at prices of $3.83 and $5.05 per share, have been repriced to $2.34 per share pursuant to the inducement agreement. The exercise of these warrants is expected to generate approximately $4.6 million in gross proceeds for the company. The shares of common stock underlying the exercised warrants have been registered for resale with the SEC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-002844), on January 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment